B. M. Smith

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia

This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.

Parallel and sequential pathways of molecular recognition of a tandem-repeat protein and its intrinsically disordered binding partner

This study investigates the kinetic mechanisms of TCF7L2 binding to β-catenin, revealing a two-site avidity model with parallel dissociation pathways.

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

This study shows that SETBP1 mutations enhance NRAS-driven MAPK signaling in leukemia, making cells sensitive to MEK inhibitor trametinib.

ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II.

This study identifies ASXL1's role in neutrophil differentiation by modulating MYC and RNA Polymerase II, showing its impact on granulocyte maturation and myeloid malignancies.

Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection

This paper enhances Cas12a's trans-cleavage activity using engineered crRNAs, enabling sensitive nucleic acid detection without amplification, achieving femtomolar detection limits for DNA, RNA, and methylated DNA.